Rhumbline Advisers reduced its stake in shares of NuVasive, Inc. (NASDAQ:NUVA) by 12.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 107,649 shares of the medical device company’s stock after selling 15,136 shares during the quarter. Rhumbline Advisers owned 0.21% of NuVasive worth $6,296,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in the stock. Alyeska Investment Group L.P. increased its position in shares of NuVasive by 13.7% in the third quarter. Alyeska Investment Group L.P. now owns 1,559,940 shares of the medical device company’s stock valued at $86,514,000 after buying an additional 187,863 shares in the last quarter. Eagle Asset Management Inc. increased its position in shares of NuVasive by 0.3% during the fourth quarter. Eagle Asset Management Inc. now owns 1,134,950 shares of the medical device company’s stock worth $65,542,000 after purchasing an additional 3,585 shares in the last quarter. American Century Companies Inc. increased its position in shares of NuVasive by 6.7% during the third quarter. American Century Companies Inc. now owns 986,812 shares of the medical device company’s stock worth $54,729,000 after purchasing an additional 62,377 shares in the last quarter. Stephens Investment Management Group LLC increased its position in shares of NuVasive by 5.2% during the fourth quarter. Stephens Investment Management Group LLC now owns 719,849 shares of the medical device company’s stock worth $42,104,000 after purchasing an additional 35,770 shares in the last quarter. Finally, Rothschild Asset Management Inc. increased its position in shares of NuVasive by 5.8% during the third quarter. Rothschild Asset Management Inc. now owns 528,023 shares of the medical device company’s stock worth $29,284,000 after purchasing an additional 28,973 shares in the last quarter.
In other NuVasive news, CEO Gregory T. Lucier acquired 6,000 shares of the company’s stock in a transaction dated Tuesday, March 6th. The shares were acquired at an average price of $50.30 per share, for a total transaction of $301,800.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.20% of the company’s stock.
A number of equities analysts have weighed in on the company. Zacks Investment Research raised NuVasive from a “hold” rating to a “buy” rating and set a $54.00 price objective on the stock in a research note on Monday, February 19th. BMO Capital Markets reissued a “buy” rating and set a $70.00 price objective on shares of NuVasive in a research note on Thursday, December 14th. BTIG Research set a $74.00 price target on NuVasive and gave the company a “buy” rating in a research note on Wednesday, December 13th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $90.00 price target on shares of NuVasive in a research note on Tuesday, January 9th. Finally, Needham & Company LLC raised NuVasive from an “underperform” rating to a “buy” rating and set a $71.00 price target on the stock in a research note on Thursday, January 4th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $68.19.
Shares of NuVasive, Inc. (NASDAQ NUVA) traded down $0.07 during midday trading on Wednesday, reaching $50.67. The company’s stock had a trading volume of 578,742 shares, compared to its average volume of 853,244. The company has a current ratio of 3.48, a quick ratio of 1.94 and a debt-to-equity ratio of 0.73. NuVasive, Inc. has a 12 month low of $44.62 and a 12 month high of $81.68. The stock has a market cap of $2,600.00, a P/E ratio of 43.68, a price-to-earnings-growth ratio of 1.30 and a beta of 0.50.
NuVasive (NASDAQ:NUVA) last released its quarterly earnings data on Monday, February 26th. The medical device company reported $0.56 EPS for the quarter, meeting analysts’ consensus estimates of $0.56. NuVasive had a return on equity of 13.40% and a net margin of 8.06%. The business had revenue of $271.70 million for the quarter, compared to the consensus estimate of $272.11 million. During the same quarter in the prior year, the business posted $0.53 EPS. The business’s revenue for the quarter was up .2% on a year-over-year basis. analysts anticipate that NuVasive, Inc. will post 2.46 EPS for the current year.
WARNING: “NuVasive, Inc. (NUVA) Shares Sold by Rhumbline Advisers” was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://ledgergazette.com/2018/03/14/nuvasive-inc-nuva-shares-sold-by-rhumbline-advisers.html.
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.